Unlocking the potential of
genomic medicine

Overview



Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary10/15/2018
- Top-line data for Parts A and B of ASCEND expected in January 2019 PHILADELPHIA , Oct. 15, 2018 /PRNewswire/ --   Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial.  The ASCEND trial is a
Toggle Summary08/29/2018
PHILADELPHIA , Aug. 29, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 5:05
Toggle Summary08/21/2018
- Initiation of enrollment in Part B of the ASCEND trial - Top-line data for Parts A and B of ASCEND expected in Q4 2018 PHILADELPHIA , Aug. 21, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced the sale of 5.1 million shares of its common stock for

Recent Presentations

More >>
Date Title
09/05/2018
06/20/2018
06/07/2018
03/28/2018
03/16/2018

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright West LLC. Minimum 15 minutes delayed.